STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

AI Summary

The article discusses how GLP-1 medications initially promoted for treating obesity are increasingly marketed and perceived as lifestyle drugs for appearance and general well-being. It also previews other pharmaceutical developments, including setbacks for Merck and Daiichi.

Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being seen — and marketed — as a way to look and feel better